GU Cancers 2020 | Immunotherapy with radiotherapy in RCC: is there a benefit?

VJOncology is committed to improving our service to you

Thomas Powles

Thomas Powles, MBBS, MRCP, MD, Barts Cancer Institute, London, UK, discusses the results of the RADVAX trial (NCT03065179) combining immune checkpoint inhibition with stereotactic radiation in metastatic renal cell carcinoma (RCC). This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter